Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch
07:03am, Saturday, 18'th Sep 2021
Their vaccines could be late to the party. But the stocks might still be big winners.
AbbVie's Pain Is Sanofi's and Regeneron's Gain
05:57am, Saturday, 18'th Sep 2021
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.
How a Covid Vaccine Could Lift Sanofi's Stock
04:30am, Friday, 17'th Sep 2021
Sanofi's Covid vaccine is now in its Phase 3 trial, and the pharmaceutical company says results could come by the end of the year.
Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business
02:22pm, Thursday, 09'th Sep 2021
GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big p
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
12:38pm, Thursday, 09'th Sep 2021
Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.
Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial
10:04am, Thursday, 09'th Sep 2021
Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test. Rilzabrutinib was Principia Biopharma Inc's one of the key candidates that Sanofi acquired last ye
The 13 Ideally Priced Most Reliable Dividends On Earth For September
11:52pm, Wednesday, 08'th Sep 2021
The 13 Ideally Priced Most Reliable Dividends On Earth For September
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
11:00am, Wednesday, 08'th Sep 2021
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.
Kadmon Stock Soars as Sanofi Buys U.S. Biotech for $1.9 Billion
07:54am, Wednesday, 08'th Sep 2021
French drugmaker Sanofi is buying Kadmon, the U.S. biopharmaceutical company, for a total equity value of $1.9 billion.
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know
06:30am, Wednesday, 08'th Sep 2021
Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar deal. Sanofi-Kadmon Deal Terms: Sano
Sanofi to acquire U.S. biopharmaceutical group Kadmon in $1.9 billion deal
01:31am, Wednesday, 08'th Sep 2021
French pharmaceutical major Sanofi SA said Wednesday that it has entered into a definitive agreement to acquire U.S.-based biopharmaceutical company Kadmon Holdings Inc.
France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 billion deal
01:15am, Wednesday, 08'th Sep 2021
French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
02:00pm, Tuesday, 31'st Aug 2021
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals
Sanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal
12:10pm, Monday, 30'th Aug 2021
Sanofi (SNY) and Regeneron (REGN)'s Dupixent meet all primary and secondary endpoints in phase III study to treat children aged six months to five years with moderate-to-severe atopic dermatitis.
Which Biotech Stock Will Shock the Market in 2022?
10:40am, Friday, 27'th Aug 2021
Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
